Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 13, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically detailing transactions related to employee benefit trusts and investment plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing reports specific share movements involving the SmithKline Beecham Employee Benefit Trust and the GlaxoSmithKline Employee Trust:
- June 7, 2005: 606 Ordinary shares sold at £13.7821 per share; 620 Ordinary shares transferred to a participant.
- June 9, 2005: 1,027 Ordinary shares sold at £13.6621 per share; 3,392 Ordinary shares transferred to a participant.
- June 10, 2005: 15,710 Ordinary shares transferred from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing clarifies that the trusts mentioned are discretionary funds where directors (specifically Mr. J S Heslop, Dr. J-P Garnier, and Dr. T Yamada) hold interests in the same capacity as other non-US or general employees. No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by directors through the SmithKline Beecham Employee Benefit Trust and the GlaxoSmithKline Employee Trust.
- Confirm the impact of the 15,710 share transfers on the outstanding share count or dilution metrics.
- Review the pricing of the sold shares (£13.7821 and £13.6621) against the market price on the transaction dates to assess execution quality.